VKTX Viking Therapeutics
- 64.450
- +1.510+2.40%
- 64.490
- +0.040+0.06%
Viking Therapeutics News
Viking Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Lian Brian
Viking Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director SINGLETON J MATTHEW
Viking Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Viking Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Viking Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Lian Brian
Viking Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director SINGLETON J MATTHEW
Viking Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Viking Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Viking Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director SINGLETON J MATTHEW
Viking Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Viking Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(4.9%)
Viking Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Lian Brian
Viking Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer ZANTE GREG
Viking Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Viking Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Viking Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Viking Therapeutics | 10-Q: Q2 2024 Earnings Report
Viking Therapeutics | 8-K: Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Viking Therapeutics | 8-K: Current report
Viking Therapeutics | 8-K: Current report
Analysis
Price Target
No Data
No Data
